IMMUNOHISTOCHEMICAL DETECTION OF HER2/NEU IN PATIENTS WITH AXILLARY LYMPH-NODE NEGATIVE BREAST-CARCINOMA - A STUDY OF EPIDEMIOLOGIC RISK FACTORS, HISTOLOGIC FEATURES, AND PROGNOSIS

被引:0
|
作者
ROSEN, PP
LESSER, ML
ARROYO, CD
CRANOR, M
BORGEN, P
NORTON, L
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT SURG,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021
[3] N SHORE UNIV HOSP,DEPT BIOSTAT,MANHASSET,NY
关键词
HER2/NEU; ONCOGENES; BREAST CANCER; PATHOLOGY PROGNOSIS;
D O I
10.1002/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Numerous studies have examined the prognostic significance of HER2/neu (HER) expression in patients with axillary lymph node negative breast carcinoma. Although some investigations suggest that the presence of the altered expression of HER is prognostically unfavorable, the subject remains controversial. This study explores the interaction of HER with three aspects of axillary lymph node negative breast carcinoma: epidemiologic risk factors, tumor histopathology, and prognosis. Methods. Immunohistochemical staining for HER was performed on 10% formalin fixed paraffin embedded primary carcinomas from 440 patients with negative axillary lymph nodes with a median follow-up of 119 months. Results. The immunohistochemical expression, or lack thereof, of HER did not prove to be prognostically significant in this group of patients with axillary lymph node negative breast carcinoma. There was also no consistent association with epidemiologic risk factors. The most striking results concerned the relationship of HER to histopathologic features of the carcinomas. Medullary carcinoma differed from other tumor types because it was HER(+) substantially less often (10%) than were other ductal (49%) or lobular (43%) carcinomas. Conclusion. The results obtained in this study suggest that the immunohistochemical demonstration of HER is not a reliable prognostic indicator for patients with axillary lymph node negative breast carcinoma. This marker was not associated with major epidemiologic risk factors; however, there was a significant correlation between HER and the phenotypic features of breast carcinoma because medullary carcinoma is rarely HER(+). Although the associations may not be a strong enough basis for refining the classification of breast carcinoma, they could be useful for diagnosing individual patients. The changes in HER that are detectable by the immunohistochemical methods used in this study probably do not occur in the earliest stages of mammary carcinogenesis.
引用
收藏
页码:1320 / 1326
页数:7
相关论文
共 50 条
  • [41] Tissue microarray-based studies of patients with lymph node-negative breast carcinoma show that HER-2/neu overexpression is an important predictive marker of poor prognosis
    Ahn, J. H.
    Kim, S. B.
    Gong, G. Y.
    Kim, M. J.
    Son, B. H.
    Ahn, S. H.
    Ahn, S. D.
    Lee, S. W.
    Kang, Y. K.
    Kim, W. K.
    BREAST, 2007, 16 : S20 - S21
  • [42] Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma:: prognostic relevance
    Peiro, Gloria
    Aranda, Francisco I.
    Adrover, Encarnal
    Niveiro, Maria
    Alenda, Cristina
    Paya, Artemio
    Segui, Javier
    HUMAN PATHOLOGY, 2007, 38 (01) : 26 - 34
  • [43] A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer
    Yue, Yuhan
    Liang, Junqing
    Wu, Yuruo
    Tong, Weibing
    Li, Dan
    Cao, Xuchen
    Wang, Xin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [44] Immunohistochemical Features of Triple Negative Breast Cancer in the Neoadjuvant Setting: Predictors Factors of Response and Evolution of HER2 Expression
    Haro Haro, Carolina
    Zuniga Gaitan, Juzzy Tatiana
    Chaachou Charradi, Anas
    Peg, Vicente
    LABORATORY INVESTIGATION, 2024, 104 (03) : S171 - S172
  • [45] MICROVESSEL DENSITY (MVD) IN DUCTAL CARCINOMA INSITU (DCIS) OF THE BREAST - COMPARISON WITH HISTOLOGIC FEATURES, HER2/NEU EXPRESSION, AND PROLIFERATION INDEX (PI)
    GUIDI, AJ
    FISCHER, L
    HARRIS, JR
    SCHNITT, SJ
    LABORATORY INVESTIGATION, 1993, 68 (01) : A16 - A16
  • [46] Retesting HER2 Status of Axillary Lymph Node Metastases for Breast Cancer Patients with Minor HER2 Amplified Clone in the Primary Tumors: Does it has Clinical Significance?
    Yang, Jieliang
    Chen, Min
    Peng, Heng
    Zhang, Zhang
    Wu, Yingyue
    Wei, Bing
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [47] HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics
    Ataseven, Beyhan
    Gologan, Daniela
    Gunesch, Angela
    Kehl, Victoria
    Hoegel, Bernhard
    Beer, Michaela
    Eiermann, Wolfgang
    BREAST CARE, 2012, 7 (06) : 465 - 470
  • [48] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor Positive, HER2 Negative Breast Cancer Patients
    Friedman-Eldar, O.
    Ozmen, T.
    Reyes, F. Valle
    Goel, N.
    Tjendra, Y.
    Moller, M.
    Kesmodel, S. B.
    Franceschi, D.
    Avisar, E.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S68 - S68
  • [49] Can the addition of regional radiotherapy counterbalance important risk factors in breast cancer patients with extracapsular invasion of axillary lymph-node metastases?
    Gruber, G
    Berclaz, G
    Altermatt, HJ
    Greiner, RH
    STRAHLENTHERAPIE UND ONKOLOGIE, 2003, 179 (10) : 661 - 666
  • [50] Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients
    Bal, Oznur
    Arslan, Ulku Yalcintas
    Durnali, Ayse
    Uyetrk, Ummugul
    Demirci, Ayse
    Tastekin, Didem
    Ekinci, Ahmet
    Esbah, Onur
    Turker, Ibrahim
    Sonmez, Ozlem Uysal
    Oksuzoglu, Berna
    JOURNAL OF BUON, 2015, 20 (01): : 28 - 34